Morning Call May 22
Health Care: Drugs
Pluristem Therapeutic (PSTI: NASDAQ)
$3.15 0.09 | 2.94%
05/22/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.06 |
| 52 Week High | 5.00 |
| 52 Week Low | 2.26 |
| Avg. Daily Vol. (Mil) | 0.16 |
| Beta (3 year) | 1.35 |
| Share Related Items | |
| Mkt Cap (Mil) | 179.43 |
| Shares Out (Mil) | 58.64 |
| Float (Mil) | 55.21 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 10.00 |
| Current Ratio | 10.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 261.95 |
| Price/Book | 2.80 |
| Price/Cash Flow | -13.90 |
| Per Share Data | |
| Earnings | -0.36 |
| Sales | 0.01 |
| Book Value | 1.09 |
| Cash Flow | -0.22 |
| Business Summary | |
|---|---|
| Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. | |
| General Information | |
| MATAM Advanced Technology Pa
Building No. 20 Haifa, 31905 |
|
| www.pluristem.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 87 | |
| CEO: Zami Aberman | |
| Short Interest | |
| Current Month (Mil) | 1.20 |
| Previous Month (Mil) | 1.21 |
| Short Interest Ratio (Days) | 8.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -18.60 |
| Return on Investments | -21.00 |
| Profitability | |
| Gross Margin | 97.40 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with PSTI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserJaheer
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User0730
Latest PSTI Headlines from TheStreet
- Pluristem Welcomes Parliamentary State Secretary Of The German Federal Ministry For Environmental, Nature Conservation And Nuclear Safety And The Chairman Of The Charite Berlin-Brandenburg Center For Regenerative Therapies 05.22.13 | 05:05 am
- Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia 05.13.13 | 03:05 am
- Pluristem Develops PLX-RAD Cells For Use In Hematology 05.07.13 | 03:05 am
- Pluristem To Present At Needham Healthcare And Oppenheimer Israeli Investment Conferences In May 2013 04.30.13 | 03:04 am
- Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety In Human Lung Models Of Pulmonary Hypertension 04.29.13 | 03:04 am
- Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine 04.18.13 | 03:04 am
- United Therapeutics Receives Regulatory Approval To Commence Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 04.11.13 | 03:04 am
- Pluristem Announces Scientific And Investment Conferences For April 2013 04.10.13 | 02:04 am
- Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury 03.20.13 | 03:03 am
- United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 02.26.13 | 09:02 am
Press Releases for PSTI
- The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI - Business Wire 12.20.12 | 07:12 pm
- Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock - Business Wire 10.12.10 | 08:10 am
- Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia - Business Wire 09.14.10 | 08:09 am
- Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients - Business Wire 08.30.10 | 08:08 am
- Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain - Business Wire 08.09.10 | 08:08 am
- Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board - Business Wire 08.04.10 | 08:08 am
- Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication - Business Wire 06.28.10 | 08:06 am
- Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences - Business Wire 05.20.10 | 08:05 am
Partner Headlines for PSTI
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Orphan Status Sought for PSTI Drug - Analyst Blog - Zacks 08.31.12 | 06:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - Zacks 08.24.12 | 06:08 pm
- Staring Down The Market With Futuristic Picks - Seeking Alpha 08.23.12 | 08:08 am
